Recent evidence has suggested that the delayed cerebral ischemic deficits that often follow surgery for aneurysmal subarachnoid hemorrhage (SAH) may be due to a proliferative vasculopathy. This vascular pathology may result from an interaction between the platelets and the vessel wall. A single-blind controlled trial of dipyridamole administration in 677 patients presenting with SAH (of whom 348 came to surgery) was undertaken to test the hypothesis that the modification of platelet behavior might reduce the incidence of ischemic deficits. Blind independent assessment of the outcome in the surgical group based on the Glasgow Outcome Scale and the specific neurological deficits revealed no significant differences between the control and treatment groups.
D
ELAYED cerebral ischemia is a major cause of mortality and morbidity following surgery for aneurysmal subarachnoid hemorrhage (SAH)? Conventionally this has been ascribed to vasospasm, but the use of vasodilating agents has not resulted in any clinical or angiographic improvements, 25 although calcium antagonists are still under active consideration. 1,2 Only maintenance of the circulating volume in its correct proportions with respect to fluid and red cell mass has had any impact. 14"2~ Recent evidence suggests that the underlying final c o m m o n pathway for delayed cerebral ischemia may be a proliferative vasculopathy 4' 16 in which platelet adherence is implicated. 21 The release of platelet emboli may then compound the problem. 7 Dipyridamole is thought to modify platelet behavior by inhibiting the platelet's ability to adhere to a damaged but unlacerated endothelium. 23 Thus, no adverse effects should occur in the hemostatic mechanisms during or after surgery. Theoretically, therefore, dipyridamole is a safe drug to use in testing the hypothesis that platelets may be involved in the production of delayed cerebral ischemia following aneurysmal SAH.
C l i n i c a l M a t e r i a l and M e t h o d s

Trial Design
Patients presenting with SAH were randomized immediately on admission and before investigation to receive either placebo or dipyridamole (Persantin) in a standard dose of 100 mg/day orally or 10 rag/day intravenously. In those coming to surgery the drug treatment was continued for 3 months postoperatively to ensure that vascular healing had occurred. Consent was obtained from the patients or their relatives for this controlled trial, which was single-blind because there was no suitable intravenous placebo available. Since the surgical investigators were aware of the treatment group to which the patient had been allocated, the outcome was assessed by a neurologist who was not aware of the randomization. The numbers of patients recruited to the trial were such that the sensitivity of the trial allowed an 80% chance of recognizing a reduction of the order of one-half in events that had a 20% incidence in the placebo population under study. Any smaller differences would not be detected. The chisquare test was used for statistical analysis. 
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Patient Population
A small pilot study was conducted in the Mersey Region from April, 1979 , to April, 1980 , to make sure that there were no adverse effects of dipyridamole on the hemostatic mechanisms in these patients. The main trial was started in May, 1981, and the last patients were recruited in November, 1983. The total population admitted to the main study was 677 patients, of whom 463 came from the Mersey Region and 214 from the Wessex Region. Of this group, 314 patients were randomly allocated to receive placebo and 336 to receive dipyridamole. The groups of patients are summarized in Table 1 . In all, 175 patients in the placebo group and 173 patients in the dipyridamole group came to surgery; 11 patients in the placebo group underwent two operations for multiple aneurysms compared with 14 in the dipyridamole group. The reasons for patients not undergoing surgery are given in Table 2 . An additional three patients had been randomly allocated to a group but refused to join the study: two of these would have been in the dipyridamole group and one in the placebo group.
Considering only those patients who came to surgery, there were no differences between the patients in the treatment and placebo groups in the following respects: their general medical condition, their age, abnormalities visible on computerized tomography scanning, vasospasm demonstrated angiographically, the siting of any aneurysm, and the median time from SAH to surgery (9.8 days in the placebo group and 9 days in the dipyridamole group). There was no difference in the incidence and frequency of rebleeding between the treatment and placebo groups ( Table 3) .
The patients' preoperative neurological grade was recorded on three occasions, based on the Hunt and Hess classification. 11 The best and worst grades were recorded following admission, together with the immediate preoperative grade. The best grade following admission revealed no differences between the treatment and the placebo group but, on analyzing the immediate preoperative grade (Table 4) , there were more patients in Grades III and IV in the dipyridamole group than there were in the placebo group and conversely more patients in Grades I and II in the placebo group. This difference did not reach significance, and is not accounted for by variations in the incidence of space-occupying hematomas, of which there were 15 in the treatment group and 21 in the placebo group.
At surgery, more patients in the placebo group were found to have subarachnoid blood, whereas more patients in the dipyridamole group were found to have tight stiff brains, even after the removal of cerebrospinal fluid and the use of mannitol. These operative features represented the only occasion in which a small statistical difference was found between the two groups (p < 0.05, Table 5 ). There was no significant difference in the overall postoperative complication rate between the placebo and the dipyridamole groups. In particular, there was no increase in the risks that might have been associated with perturbation of the hemostatic mechanisms; for example, developing a postoperative hematoma or a deep venous thrombosis with or without pulmonary embolus (Table 6 ). Dipyridamole itself may cause headache and gastrointestinal upset with profuse diarrhea. The latter caused a problem in two of our postoperative SAH patients, and in these the drug had to be stopped to control the diarrhea. Operative outcome (% of cases)
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Results
The outcome was assessed 3 months postoperatively by a neurologist in each center. There was no significant difference in the overall outcome, as judged by the Glasgow Outcome Scale, ~2 between the placebo-and the dipyridamole-treated patients (Table 7 ). There were also no differences in a separate analysis of the type of disability (for example, the presence or absence of aphasia, hemiparesis, or personality changes). Analysis of neurological deterioration occurring in patients following surgery (excluding those in whom the deterioration could be ascribed to a cause other than that of delayed ischemia) revealed no difference in outcome between the treatment and placebo groups.
Discussion
Although advances, particularly with respect to anesthetic and microsurgical techniques, have led to improvements in the results of surgery for aneurysmal SAH, ~3 delayed cerebral ischemia remains a major cause of death and disability in these patients. 5 Vasospasm has long been considered a major cause of this deficit, but the use of a large variety of vasodilating agents has not resulted in any significant improvement in outcome, 25 although undoubtedly many vasospastic substances are released into the cerebrospinal fluid following SAH. Recently, evidence has accrued suggesting that the basic underlying problem may be proliferative vasculopathy. 4"~6 In a postmortem study Crompton 5 noted, in addition to patchy cerebral infarction, the presence of necrosis in the media of large vessels and marked intimal changes in these vessels, the smaller arteries, and the capillaries. Hughes and SchianchP ~ confirmed the presence of necrosis up to 17 days postictus and thereafter of subintimal fibrosis in vessels that were in direct relationship to areas of ischemic change in the brain substance. However, they suggested that the vascular changes were the result rather than the cause of vasospasm, because similar changes had been reported in patients suffering ischemia from other causes such as endarteritis obliterans.
Mizukami, et al., ~5 reported serial pathological studies in larger vessels and described acute, subacute, and chronic stages. Acute vasospasm lasted less than 24 hours, and resulted from a reversible contraction of the medial smooth-muscle cells. Persistence of contraction beyond this time limit was associated with medial thickening and necrosis, together with swelling of the intima. The latter was symmetrical, and platelet aggregation occurred. Later in the natural history, chronic changes were seen, including fibrosis in the media and focal endothelial proliferation with associated thrombus formation. Evidence from experimentally produced SAH has suggested that, in addition to the responses described within the vessel wall, loss of endothelium can occur. It has been suggested that the loss is due to increased shear stress associated with an increased flow velocity through an area of vascular narrowing, 7 but more importantly collagen filaments are exposed, to which platelets can adhere. This endothelial damage occurring as part of the inflammatory and vascular response to SAH may be compounded by other factors during investigation and surgery, such as angiography or temporary clipping. 19 The role of platelets in these events ~,~ not clear but they do adhere at such sites. There is evidence that the release of platelet factors, including platelet factor IV, into the vessel wall can result in medial hypertrophy, not only at the site of adherence but more remotely, 21 and hence could lead to vessel narrowing. Furthermore, non-homogeneous disaggregation occurs during platelet thrombus formation; this leads to the release of small platelet emboli which may then become impacted in the distal circulation. 7 The hypertrophy together with the lodging of the platelet emboli in the distal circulation could result in the scattered ischemic lesions that are seen in patients studied post mortem. Phospholipid, both in the endothelium of the vessel wall and in the platelet envelope, is metabolized through the intermediate compounds, arachidonic acid and endoperoxides, to prostacyclin in the vessel wall and thromboxane in the platelets. Prostacyclin is a vasodilator and thromboxane a vasoconstrictor. When the cyclic adenosine monophosphate (cAMP) concentration falls, calcium ions are released from storage, causing platelet activation during which the platelet loses its discoid shape, puts out pseudopodia, and can adhere to the vessel wall. Prostacyclin stimulates enzymatic production of cAMP while thromboxane inhibits the same reaction. Thus, physiologically, there is a balance between thromboxane-initiating and prostacyclin-inhibiting platelet aggregation, in addition to their respective vasoactive roles.
Dipyridamole is thought to modify platelet behavior principally by maintaining AMP in its cyclic form by both stimulating its enzymatic production and reducing its active degradationfl 3 It should therefore inhibit the platelet's ability to adhere to a damaged but structurally intact endothelium. However, if the endothelium is lacerated, the thromboxane level is increased relative to that of prostacyclin because endoperoxide released from the damaged endothelium is converted to thromboxane by the platelets. No adverse effects should therefore occur in the hemostatic mechanisms during or after surgery. Theoretically, therefore, dipyridamole is an ideal drug for testing the hypothesis that the platelets may be involved in the production of delayed cerebral ischemia following aneurysmal SAH.
In this trial, the patients were randomly assigned equally to the placebo and the dipyridamole groups. Of those coming to surgery, the condition of the patients in the two groups was statistically similar except that more patients in the placebo group were found to have subarachnoid blood at operation, whereas more in the dipyridamole group had tight stiff brains even after the removal of cerebrospinal fluid and the use of osmotic diuretic agents. The reason for this statistical difference between the two groups is not clear, although it is not surprising in a population of this size that one feature should show a difference. Indeed, had the population been larger, the randomization might have smoothed out these apparently counterbalancing adverse factors in terms of outcome. However, these factors may also reflect some other difference in the two populations; for example, the stiffness of the brain in the dipyridamole group could be the result of the mild vasodilating properties of dipyridamole. 9 Thus, preoperatively, the placebo and treatment groups were essentially similar.
No difference has been detected in the outcome following surgery within the limits of the sensitivity of this trial. Subsequent analysis, in which other causes of postoperative deterioration were excluded, revealed no difference between the treatment and placebo groups with respect to presumed delayed ischemic complications. We accepted the recommended dose of dipyridamole as the result of previous work on blood levels. J8 We did not assess blood levels, as this is difficult, but an assessment of the effects of the dosage used on some parameters of platelet function was carried out as part of this study in the University Haematology Department at the Royal Liverpool Hospital (G Satchi, et al., in preparation). No differences were found between the placebo and treatment groups in respect of platelet count and volume, total nucleotides, adenosine triphosphate:adenosine diphosphate ratios, fibrinopeptin A, thromboglobulin, and antithrombin. Thus, it is possible that we have used an inadequate dose. However, the effectiveness of dipyridamole has recently been questioned. 6 Where does the future lie for modification of the interaction between the platelet and the vessel wall? The development of a stable prostacyclin analogue that does not have the marked systemic effects of prostacyclin might be of value, as experimental administration of prostacyclin inhibits the immediate vertebrobasilar constriction produced by the application of oxyhemoglobin. 17 However, there is conflicting evidence as to whether prostacyclin can affect the vascular narrowing present 24 hours or more after experimental injection of blood into the subarachnoid space. 3'24 The difficulty with thromboxane A2 antagonists is that all the present drugs significantly increase the bleeding time. The same problem may occur with thromboxane synthetase inhibitors and with drugs that inhibit cyclo-oxygenase (such as aspirin and ticlopidine) which is involved in the enzymatic conversion of arachidonic acid to endoperoxides and, hence, either inhibitor will affect thromboxane production.
It is of interest that nimodipine is also under consideration as a drug effective in reducing the risks of postoperative cerebral ischemia. ~ Recent evidence has suggested that nimodipine has no effect on the degree of contraction of vessels as judged angiographicallyy 2 but it is possible that it influences the handling of calcium ions within the envelope of the platelet, thus modifying the platelet's ability to adhere to the vascular endothelium.
